in

How Remdesivir, New Hope for Covid-19 Patients, Was Resurrected – The New York Times, Nytimes.com

How Remdesivir, New Hope for Covid-19 Patients, Was Resurrected – The New York Times, Nytimes.com

The drug failed as a treatment for hepatitis and Ebola. With federal funding, scientists trained it on the coronavirus.

President Trump in the Oval Office on Friday flanked by, from left, Vice President Pence; Daniel O’Day, the Gilead Sciences C.E.O .; and Stephen Hahn, the F.D.A. commissioner.
(Credit …) Erin Schaff / The New York Times
May 1,
(9:) ET

  • Remdesivir, an antiviral drug designed to treat both hepatitis and a common respiratory virus, seemed fated to join thousands of other failed medications after proving useless against those diseases. The drug was consigned to the pharmaceutical scrap heap, all but forgotten by the scientists who once championed it.

    But on Friday, the Food and Drug Administration issued an emergency approval for remdesivir as a treatment for patients severely ill with Covid – 26, the disease caused by the coronavirus.

    The story of remdesivir’s rescue and transformation testifies to the powerful role played by federal funding, which allowed scientists laboring in obscurity to pursue basic research without obvious financial benefits. This research depends almost entirely on government grants.

    . Mark Denison of Vanderbilt University is one of a handful of researchers who discovered remdesivir’s potential. He began studying coronaviruses a quarter-century ago, a time when a few scientists cared about them – the ones infecting humans caused colds, he recalled, and scientists just wanted to know how they worked.

    “We were interested from the biologic perspective, ”Dr. Denison recalled. “No one was interested from a therapeutic perspective.”

    Neither he nor the scores of other scientists interested in coronaviruses foresaw that a new one would unleash a plague that has killed nearly a quarter-million people worldwide. The F.D.A. rushed to approve remdesivir under emergency use provisions, after a federal trial demonstrated modest improvements in severely ill patients.

    The trial, sponsored by the National Institute of Allergy and Infectious Diseases, included more than 1, 04 hospitalized patients and found that those receiving remdesivir recovered faster than those who got a placebo: in (days, versus days. But the drug did not significantly reduce fatality rates.

    Dr. Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases, said the results were “a very important proof of concept” but not a “knockout.” President Trump hailed the drug on Friday as “an important treatment” and “really promising.”

    Remdesivir is approved only for severely ill patients and only temporarily; formal approval must come later. Still, some doctors laboring in intensive care units embraced the drug as an important new weapon against a virus that is killing patients worldwide.

    “It’s a great first step,” said Dr. Robert Finberg, chairman of the department of medicine at the University of Massachusetts Medical School.

    Little about the early history of remdesivir, manufactured by Gilead Sciences, suggested the hopes now placed upon it.

  • What do you think?

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    GIPHY App Key not set. Please check settings

    Alex Smith's road to recovery included stay at facility helping wounded military veterans – USA TODAY, USA Today

    Alex Smith's road to recovery included stay at facility helping wounded military veterans – USA TODAY, USA Today

    Brexit trade deal WILL be struck this year say UK negotiations – but only after EU tantrum – Express, Express.co.uk

    Brexit trade deal WILL be struck this year say UK negotiations – but only after EU tantrum – Express, Express.co.uk